GEMFIBROZIL

N/A

Manufactured by Parke-Davis Div of Pfizer Inc

30,260 FDA adverse event reports analyzed

Last updated: 2026-04-14

About GEMFIBROZIL

GEMFIBROZIL is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Parke-Davis Div of Pfizer Inc. The most commonly reported adverse reactions for GEMFIBROZIL include NAUSEA, FATIGUE, DRUG INEFFECTIVE, DIARRHOEA, PAIN. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for GEMFIBROZIL.

Top Adverse Reactions

NAUSEA883 reports
FATIGUE824 reports
DRUG INEFFECTIVE766 reports
DIARRHOEA725 reports
PAIN692 reports
DIZZINESS617 reports
RHABDOMYOLYSIS604 reports
DYSPNOEA598 reports
ASTHENIA597 reports
HEADACHE561 reports
RENAL FAILURE559 reports
VOMITING509 reports
CHRONIC KIDNEY DISEASE484 reports
DRUG INTERACTION464 reports
PAIN IN EXTREMITY455 reports
FALL452 reports
ACUTE KIDNEY INJURY441 reports
DRUG HYPERSENSITIVITY436 reports
ARTHRALGIA435 reports
WEIGHT DECREASED428 reports
ANXIETY422 reports
MYALGIA419 reports
MALAISE415 reports
MYOCARDIAL INFARCTION413 reports
BLOOD GLUCOSE INCREASED405 reports
PNEUMONIA393 reports
RENAL FAILURE ACUTE372 reports
DEATH369 reports
RASH366 reports
DEPRESSION353 reports
CHEST PAIN352 reports
DIABETES MELLITUS342 reports
OFF LABEL USE339 reports
BACK PAIN334 reports
INSOMNIA333 reports
ANAEMIA319 reports
PRURITUS318 reports
HYPERTENSION311 reports
CARDIAC FAILURE CONGESTIVE309 reports
ABDOMINAL PAIN308 reports
COUGH305 reports
WEIGHT INCREASED290 reports
PYREXIA283 reports
GAIT DISTURBANCE277 reports
HYPOTENSION269 reports
CEREBROVASCULAR ACCIDENT268 reports
ABDOMINAL PAIN UPPER260 reports
DECREASED APPETITE254 reports
OEDEMA PERIPHERAL252 reports
BLOOD TRIGLYCERIDES INCREASED243 reports
FEELING ABNORMAL243 reports
CONSTIPATION241 reports
URINARY TRACT INFECTION240 reports
PANCREATITIS229 reports
BLOOD CHOLESTEROL INCREASED227 reports
MUSCLE SPASMS227 reports
DEHYDRATION223 reports
MUSCULAR WEAKNESS217 reports
CORONARY ARTERY DISEASE216 reports
FLUSHING210 reports
TYPE 2 DIABETES MELLITUS209 reports
HYPOAESTHESIA205 reports
PARAESTHESIA203 reports
BLOOD PRESSURE INCREASED201 reports
GASTROINTESTINAL HAEMORRHAGE201 reports
SOMNOLENCE196 reports
CONDITION AGGRAVATED195 reports
TREMOR194 reports
ATRIAL FIBRILLATION192 reports
CONFUSIONAL STATE191 reports
BLOOD CREATINE PHOSPHOKINASE INCREASED181 reports
BLOOD CREATININE INCREASED179 reports
HYPERHIDROSIS178 reports
DRUG DOSE OMISSION174 reports
HAEMOGLOBIN DECREASED173 reports
GASTROOESOPHAGEAL REFLUX DISEASE172 reports
NEUROPATHY PERIPHERAL172 reports
RENAL IMPAIRMENT165 reports
LOSS OF CONSCIOUSNESS164 reports
ABDOMINAL DISCOMFORT161 reports
VISION BLURRED159 reports
EMOTIONAL DISTRESS158 reports
END STAGE RENAL DISEASE158 reports
HYPERGLYCAEMIA155 reports
ALOPECIA154 reports
MEMORY IMPAIRMENT153 reports
SEPSIS146 reports
EPISTAXIS145 reports
INJECTION SITE PAIN144 reports
SYNCOPE142 reports
HYPOGLYCAEMIA139 reports
DYSPEPSIA137 reports
INJURY137 reports
ABDOMINAL DISTENSION136 reports
ERYTHEMA135 reports
CARDIAC DISORDER134 reports
CHRONIC OBSTRUCTIVE PULMONARY DISEASE134 reports
NASOPHARYNGITIS134 reports
BLOOD GLUCOSE DECREASED129 reports
SINUSITIS129 reports

Report Outcomes

Out of 14,946 classified reports for GEMFIBROZIL:

Serious 66.7%Non-Serious 33.3%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Male8,017 (56.2%)
Female6,219 (43.6%)
Unknown24 (0.2%)

Reports by Age

Age 65314 reports
Age 60308 reports
Age 63303 reports
Age 69295 reports
Age 61288 reports
Age 62286 reports
Age 70284 reports
Age 67283 reports
Age 66277 reports
Age 56275 reports
Age 64269 reports
Age 59258 reports
Age 68257 reports
Age 72256 reports
Age 57252 reports
Age 54249 reports
Age 71233 reports
Age 58230 reports
Age 55229 reports
Age 73224 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with GEMFIBROZIL?

This profile reflects 30,260 FDA FAERS reports that mention GEMFIBROZIL. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for GEMFIBROZIL?

Frequently reported terms in FAERS include NAUSEA, FATIGUE, DRUG INEFFECTIVE, DIARRHOEA, PAIN, DIZZINESS. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures GEMFIBROZIL?

Labeling and FAERS entries often list Parke-Davis Div of Pfizer Inc in connection with GEMFIBROZIL. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.